156 related articles for article (PubMed ID: 34251576)
1. NCOA3 is a critical oncogene in thyroid cancer via the modulation of major signaling pathways.
Li Y; Liang J; Dang H; Zhang R; Chen P; Shao Y
Endocrine; 2022 Jan; 75(1):149-158. PubMed ID: 34251576
[TBL] [Abstract][Full Text] [Related]
2. Frequent amplification of AIB1, a critical oncogene modulating major signaling pathways, is associated with poor survival in gastric cancer.
Shi J; Liu W; Sui F; Lu R; He Q; Yang Q; Lv H; Shi B; Hou P
Oncotarget; 2015 Jun; 6(16):14344-59. PubMed ID: 25970779
[TBL] [Abstract][Full Text] [Related]
3. N-cadherin promotes thyroid tumorigenesis through modulating major signaling pathways.
Da C; Wu K; Yue C; Bai P; Wang R; Wang G; Zhao M; Lv Y; Hou P
Oncotarget; 2017 Jan; 8(5):8131-8142. PubMed ID: 28042956
[TBL] [Abstract][Full Text] [Related]
4. SRC-3/AIB1: transcriptional coactivator in oncogenesis.
Yan J; Tsai SY; Tsai MJ
Acta Pharmacol Sin; 2006 Apr; 27(4):387-94. PubMed ID: 16539836
[TBL] [Abstract][Full Text] [Related]
5. SRC-3 inhibition blocks tumor growth of pancreatic ductal adenocarcinoma.
Song X; Chen H; Zhang C; Yu Y; Chen Z; Liang H; Van Buren G; McElhany AL; Fisher WE; Lonard DM; O'Malley BW; Wang J
Cancer Lett; 2019 Feb; 442():310-319. PubMed ID: 30423406
[TBL] [Abstract][Full Text] [Related]
6. The cooperative function of nuclear receptor coactivator 1 (NCOA1) and NCOA3 in placental development and embryo survival.
Chen X; Liu Z; Xu J
Mol Endocrinol; 2010 Oct; 24(10):1917-34. PubMed ID: 20685850
[TBL] [Abstract][Full Text] [Related]
7. NCOA3 coactivator is a transcriptional target of XBP1 and regulates PERK-eIF2α-ATF4 signalling in breast cancer.
Gupta A; Hossain MM; Miller N; Kerin M; Callagy G; Gupta S
Oncogene; 2016 Nov; 35(45):5860-5871. PubMed ID: 27109102
[TBL] [Abstract][Full Text] [Related]
8. PAX3 is a novel tumor suppressor by regulating the activities of major signaling pathways and transcription factor FOXO3a in thyroid cancer.
Liu W; Sui F; Liu J; Wang M; Tian S; Ji M; Shi B; Hou P
Oncotarget; 2016 Aug; 7(34):54744-54757. PubMed ID: 27458157
[TBL] [Abstract][Full Text] [Related]
9. Circ_0001667 knockdown blocks cancer progression and attenuates adriamycin resistance by depleting NCOA3 via releasing miR-4458 in breast cancer.
Cui Y; Fan J; Shi W; Zhou Z
Drug Dev Res; 2022 Feb; 83(1):75-87. PubMed ID: 34227151
[TBL] [Abstract][Full Text] [Related]
10. Nuclear Receptor Coactivator NCOA3 Regulates UV Radiation-Induced DNA Damage and Melanoma Susceptibility.
de Semir D; Bezrookove V; Nosrati M; Dar AA; Miller JR; Leong SP; Kim KB; Liao W; Soroceanu L; McAllister S; Debs RJ; Schadendorf D; Leachman SA; Cleaver JE; Kashani-Sabet M
Cancer Res; 2021 Jun; 81(11):2956-2969. PubMed ID: 33766890
[TBL] [Abstract][Full Text] [Related]
11. A potential target for liver cancer management, lysophosphatidic acid receptor 6 (LPAR6), is transcriptionally up-regulated by the NCOA3 coactivator.
Zheng X; Jia Y; Qiu L; Zeng X; Xu L; Wei M; Huang C; Liu C; Chen L; Han J
J Biol Chem; 2020 Feb; 295(6):1474-1488. PubMed ID: 31914406
[TBL] [Abstract][Full Text] [Related]
12. MAD2L2 inhibits colorectal cancer growth by promoting NCOA3 ubiquitination and degradation.
Li Y; Li L; Chen M; Yu X; Gu Z; Qiu H; Qin G; Long Q; Fu X; Liu T; Li W; Huang W; Shi D; Kang T; Luo M; Wu X; Deng W
Mol Oncol; 2018 Mar; 12(3):391-405. PubMed ID: 29360267
[TBL] [Abstract][Full Text] [Related]
13. NCoA3 upregulation in breast cancer‑associated adipocytes elicits an inflammatory profile.
Lira MC; Rosa FD; Aiello I; Machado MS; Palma AG; Paz L; Güemes MCS; Burlando S; Azurmendi PJ; Paladino N; Costas MA; Rubio MF
Oncol Rep; 2023 May; 49(5):. PubMed ID: 37026525
[TBL] [Abstract][Full Text] [Related]
14. Positive Feedback Loops Between NrCAM and Major Signaling Pathways Contribute to Thyroid Tumorigenesis.
Zhang Y; Sui F; Ma J; Ren X; Guan H; Yang Q; Shi J; Ji M; Shi B; Sun Y; Hou P
J Clin Endocrinol Metab; 2017 Feb; 102(2):613-624. PubMed ID: 27732334
[TBL] [Abstract][Full Text] [Related]
15. Decreased expression of microRNA-17 and microRNA-20b promotes breast cancer resistance to taxol therapy by upregulation of NCOA3.
Ao X; Nie P; Wu B; Xu W; Zhang T; Wang S; Chang H; Zou Z
Cell Death Dis; 2016 Nov; 7(11):e2463. PubMed ID: 27831559
[TBL] [Abstract][Full Text] [Related]
16. ZIC1 is a putative tumor suppressor in thyroid cancer by modulating major signaling pathways and transcription factor FOXO3a.
Qiang W; Zhao Y; Yang Q; Liu W; Guan H; Lv S; Ji M; Shi B; Hou P
J Clin Endocrinol Metab; 2014 Jul; 99(7):E1163-72. PubMed ID: 24684457
[TBL] [Abstract][Full Text] [Related]
17. AIB1/SRC-3/NCOA3 function in estrogen receptor alpha positive breast cancer.
Kiliti AJ; Sharif GM; Martin MB; Wellstein A; Riegel AT
Front Endocrinol (Lausanne); 2023; 14():1250218. PubMed ID: 37711895
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of EHF contributes to thyroid tumorigenesis through transcriptionally regulating HER2 and HER3.
Lv Y; Sui F; Ma J; Ren X; Yang Q; Zhang Y; Guan H; Shi B; Hou P; Ji M
Oncotarget; 2016 Sep; 7(36):57978-57990. PubMed ID: 27517321
[TBL] [Abstract][Full Text] [Related]
19. Targeting the NCOA3-SP1-TERT axis for tumor growth in hepatocellular carcinoma.
Li W; Yan Y; Zheng Z; Zhu Q; Long Q; Sui S; Luo M; Chen M; Li Y; Hua Y; Deng W; Lai R; Li L
Cell Death Dis; 2020 Nov; 11(11):1011. PubMed ID: 33239622
[TBL] [Abstract][Full Text] [Related]
20. Amplified in breast cancer 1 promotes colorectal cancer progression through enhancing notch signaling.
Mo P; Zhou Q; Guan L; Wang Y; Wang W; Miao M; Tong Z; Li M; Majaz S; Liu Y; Su G; Xu J; Yu C
Oncogene; 2015 Jul; 34(30):3935-3945. PubMed ID: 25263446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
